Semin intervent Radiol 2005; 22(2): 130-138
DOI: 10.1055/s-2005-871868
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Pharmaceuticals for Intra-arterial Therapy

Aalpen A. Patel1 , Jeffery A. Solomon1 , Michael C. Soulen1
  • 1Department of Radiology, Interventional Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
28 June 2005 (online)

ABSTRACT

Clinical pharmacology may be defined as the branch of medicine concerned with the therapeutic agents used in the prevention, treatment, and control of disease. Pharmaceuticals are the specific agents used to combat disease. Hence, many of the agents used by the interventionalist may be considered pharmaceuticals. Safe and effective use of these therapeutics requires understanding of vascular anatomy and disease pathology, proper technique, and knowledge of the therapeutic agents. This article reviews many of the agents available and some that are on the horizon. The future of transarterial therapies is bright and holds many promises.

REFERENCES

  • 1 Stedman's Medical Dictionary. 25th ed. Baltimore; Williams & Wilkins 1990: 1177
  • 2 Dawbarn R HM. The starvation operation for malignancy in the external carotid area.  JAMA. 1904;  43 792-795
  • 3 Patel A A, Soulen M C. Agents for small vessel/tissue embolization and transcatheter tissue ablation: current status and the future. In: Baum SA, Pentecost MJ Interventional Radiology. 2nd ed. Philadelphia; Lippincott Williams and Wilkins 2005: 169-175 In press
  • 4 Levin D C, Beckmann C F, Hillman B. Experimental determination of flow patterns of gelfoam emboli: safety implications.  AJR Am J Roentgenol. 1980;  134 525-528
  • 5 Ohyama T, Nishide T, Iwata H et al.. Immobilization of basic fibroblast growth factor on a platinum microcoil to enhance tissue organization and in intracranial aneurysms.  J Neurosurg. 2005;  102 109-115
  • 6 Marx W E, Cloft H J, Helm G A et al.. Endovascular treatment of experimental aneurysms by use of biologically modified embolic devices: coil-mediated intraaneurysmal delivery of fibroblast tissue allografts.  AJNR Am J Neuroradiol. 2001;  22 323-333
  • 7 Murayama Y, Vinuela F, Suzuki Y et al.. Development of the biologically active Guglielmi detachable coil for the treatment of cerebral aneurysms. Part II: an experimental study in a swine aneurysm model.  AJNR Am J Neuroradiol. 1999;  20 1992-1999
  • 8 Murayama Y, Tateshima S, Gonzalez N et al.. Matrix and bioabsorbable polymeric coils accelerate healing of intracranial aneurysms: long-term experimental study.  Stroke. 2003;  34 2031-2037
  • 9 Ribourtout E, Raymond J. Gene therapy and endovascular treatment of intracranial aneurysms.  Stroke. 2004;  35 786-793
  • 10 Haisma H J, Grill J, Curiel D T et al.. Targeting of adenoviral vectors through a bispecific single-chain antibody.  Cancer Gene Ther. 2000;  7 901-904
  • 11 Klugherz B D, Song C, DeFelice S et al.. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus.  Hum Gene Ther. 2002;  13 443-454
  • 12 Abrahams J M, Song C, DeFelice S, Grady M S, Diamond S L, Levy R J. Endovascular microcoil gene delivery using immobilized anti-adenovirus antibody for vector tethering.  Stroke. 2002;  33 1376-1382
  • 13 Barth K H, Strandberg J D, White Jr R I. Long-term follow-up of transcatheter embolization with autologous clot, Oxycel, and Gelfoam in domestic swine.  Invest Radiol. 1977;  12 273-280
  • 14 Barbolt T A, Odin M, Leger M et al.. Pre-clinical subdural tissue reaction and absorption study of absorbable hemostatic devices.  Neurol Res. 2001;  23 537-542
  • 15 Kaufman S L, Strandberg J D, Barth K L, White Jr R I. Transcatheter embolization with microfibrillar collagen in swine.  Invest Radiol. 1978;  13 200-204
  • 16 Daniels J R, Kerlan R K, Dodds L et al.. Peripheral hepatic arterial embolization with crosslinked collagen fibers.  Invest Radiol. 1987;  22 126-131
  • 17 Sniderman K W, Sos T A, Alonso D R. Transcatheter embolization with Gelfoam and Avitene: the effect of Sotradecol on the duration of arterial occlusion.  Invest Radiol. 1981;  16 501-507
  • 18 Tellez C, Benson III A B, Lyster M T et al.. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature.  Cancer. 1998;  82 1250-1259
  • 19 Aigner K R. Intra-arterial infusion: overview and novel approaches.  Semin Surg Oncol. 1998;  14 248-253
  • 20 Kumada T, Nakano S, Sone Y et al.. Clinical effectiveness of degradable starch microspheres (DSM) in patients with liver cancer.  Gan To Kagaku Ryoho. 1999;  26 1678-1683
  • 21 Civalleri D, Esposito M, Fulco R A et al.. Liver and tumor uptake and plasma pharmacokinetics of arterial cisplatin administered with and without starch microspheres in patients with liver metastases.  Cancer. 1991;  68 988-994
  • 22 Hakansson L, Hakansson A, Morales O, Thorelius L, Warfving T. Spherex (degradable starch microspheres) chemo-occlusion-enhancement of tumor drug concentration and therapeutic efficacy: an overview.  Semin Oncol. 1997;  24(suppl 6) S6-S109
  • 23 Castañeda-Zuñiga W R, Sanchez R, Amplatz K. Experimental observations on short- and long-term effects of arterial occlusion with Ivalon.  Radiology. 1978;  126 783-785
  • 24 Bandi R, Shetty P C, Sharma R P et al.. Superselective arterial embolization for the treatment of lower gastrointestinal hemorrhage.  J Vasc Interv Radiol. 2001;  12 1399-1405
  • 25 www.bostonscientific.com
  • 26 www.biocompatibles.com
  • 27 www.biospheremed.com
  • 28 Laurent A, Beaujeux R, Wassef M et al.. Trisacryl gelatin microspheres for therapeutic embolization, I: development and in vitro evaluation.  AJNR Am J Neuroradiol. 1996;  17 533-540
  • 29 Beaujeux R, Laurent A, Wassef M et al.. Trisacryl gelatin microspheres for therapeutic embolization, II: preliminary clinical evaluation in tumors and arteriovenous malformation.  AJNR Am J Neuroradiol. 1996;  17 541-548
  • 30 Shapiro A MJ, Lakey J RT, Ryan E A et al.. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.  N Engl J Med. 2000;  343 230-238
  • 31 Soulen M C, Faykus M H, Shlansky-Goldberg R D et al.. Elective embolization for prevention of hemorrhage from renal angiomyolipomas.  J Vasc Interv Radiol. 1994;  5 587-591
  • 32 Wright K C, Loh G, Wallace S et al.. Experimental evaluation of ethanol-ethiodol for transcatheter renal embolization.  Cardiovasc Intervent Radiol. 1990;  13 309-313
  • 33 Pollak J S, White R I. The use of cyanoacrylate adhesives in peripheral embolization.  J Vasc Interv Radiol. 2001;  12 907-913
  • 34 www.jnj.com/news/jnj_news/20020307_1752.htm
  • 35 Hunter D W, Casteñeda-Zuñiga W R, Coleman C C et al.. Spermatic vein embolization with hot contrast medium or detachable balloons.  Semin Interv Radiol. 1984;  1 163-166
  • 36 http://www.sirtex.com/
  • 37 Gray B N, Van Hazel G, Anderson J et al.. Randomised phase II trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone on advanced colorectal hepatic metastases. Presented at the 2002 meeting of the American Society of Clinical Oncology (ASCO). Abstract number 599 (100474)
  • 38 Gray B, Van Hazel G, Hope M et al.. Randomised trial of SIR-Spheres plus chemotherapy versus chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.  Ann Oncol. 2001;  12 1711-1720
  • 39 www.TheraSphere.com
  • 40 Moroz P, Jones S K, Gray B N. Tumour response to arterial embolization hyperthermia and direct injection hyperthermia in a rabbit liver tumour model.  J Surg Oncol. 2002;  80 149-156
  • 41 Johnson J. Magnetic Targeted Carriers: An Innovative Drug Delivery Technology; Spring 2002 (Premier Issue). Available at: www.MagneticsMagazine.com

Aalpen A PatelM.D. 

Department of Radiology, Interventional Radiology, Hospital of the University of Pennsylvania

3400 Spruce Street, Philadelphia, PA 19104